Volume 25, Number 12—December 2019
Research
High Prevalence of Macrolide-Resistant Bordetella pertussis and ptxP1 Genotype, Mainland China, 2014–2016
Table 2
Drug | No. isolates | E‐test, mg/L |
Kirby-Bauer disk diffusion |
||||
---|---|---|---|---|---|---|---|
MIC50 | MIC90 | MIC range | Range of inhibition zone, mm | Rate of susceptibility, %† | |||
Erythromycin | 335 | >256 | >256 | 0.032 to >256 | 668 | 12.5% | |
Clindamycin | 335 | >256 | >256 | 0.25 to >256 | NT | NT | |
Amoxicillin | 335 | 0.5 | 1 | 0.125 to 2 | NT | NT | |
Ampicillin | 335 | 0.25 | 0.5 | 0.032 to 1 | NT | NT | |
Levofloxacin | 335 | 0.5 | 1 | 0.064 to 1 | NT | NT | |
Sulfamethoxazole | 335 | 0.064 | 0.25 | 0.002 to 0.5 | NT | NT | |
Ceftriaxone | 335 | 0.25 | 0.5 | 0.064 to 2 | NT | NT | |
Amikacin | 222 | 8 | 8 | 2 to 32 | NT | NT | |
Clarithromycin | 83 | >256 | >256 | 0.032 to >256 | NT | NT | |
Azithromycin | 83 | >256 | >256 | 0.016 to >256 | NT | NT | |
Doxycycline | 310 | 8 | 8 | 1 to 16 | NT | NT | |
Aztreonam | 86 | 8 | 32 | 4 to 32 | NT | NT |
*NT, not tested in this study.
†An inhibition diameter >42 mm suggested that the isolate was susceptible to erythromycin.
1These authors contributed equally to this article.
Page created: November 18, 2019
Page updated: November 18, 2019
Page reviewed: November 18, 2019
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.